Your browser doesn't support javascript.
loading
TET1 and TDG Suppress Inflammatory Response in Intestinal Tumorigenesis: Implications for Colorectal Tumors With the CpG Island Methylator Phenotype.
Tricarico, Rossella; Madzo, Jozef; Scher, Gabrielle; Cohen, Maya; Jelinek, Jaroslav; Maegawa, Shinji; Nagarathinam, Rajeswari; Scher, Carly; Chang, Wen-Chi; Nicolas, Emmanuelle; Slifker, Michael; Zhou, Yan; Devarajan, Karthik; Cai, Kathy Q; Kwok, Tim; Nakajima, Pamela; Xu, Jinfei; Mancuso, Pietro; Doneddu, Valentina; Bagella, Luigi; Williams, Riley; Balachandran, Siddharth; Maskalenko, Nicholas; Campbell, Kerry; Ma, Xueying; Cañadas, Israel; Viana-Errasti, Julen; Moreno, Victor; Valle, Laura; Grivennikov, Sergei; Peshkova, Iuliia; Kurilenko, Natalia; Mazitova, Aleksandra; Koltsova, Ekaterina; Lee, Hayan; Walsh, Martin; Duttweiler, Reuben; Whetstine, Johnathan R; Yen, Timothy J; Issa, Jean-Pierre; Bellacosa, Alfonso.
Afiliación
  • Tricarico R; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Madzo J; Coriell Institute for Medical Research, Camden, New Jersey.
  • Scher G; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Cohen M; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Jelinek J; Coriell Institute for Medical Research, Camden, New Jersey.
  • Maegawa S; University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Nagarathinam R; Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Scher C; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Chang WC; Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Nicolas E; Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Slifker M; Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Zhou Y; Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Devarajan K; Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Cai KQ; Experimental Histopathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Kwok T; Cell Culture Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Nakajima P; Cell Culture Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Xu J; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Mancuso P; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Doneddu V; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Bagella L; Department of Biomedical Sciences, University of Sassari, Sassari, Italy; Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania.
  • Williams R; Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Balachandran S; Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Maskalenko N; Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Campbell K; Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Ma X; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Cañadas I; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Viana-Errasti J; Hereditary Cancer Program Catalan Institute of Oncology, Oncobell Program, Investigación Biomédica de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.
  • Moreno V; Oncology Data Analytics Program, Catalan Institute of Oncology, Oncobell Program, Investigación Biomédica de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública, Madrid, Spain; Department of Clinical Sciences, Faculty of
  • Valle L; Hereditary Cancer Program Catalan Institute of Oncology, Oncobell Program, Investigación Biomédica de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
  • Grivennikov S; Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Medicine and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
  • Peshkova I; Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Medicine and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
  • Kurilenko N; Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Medicine and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
  • Mazitova A; Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Medicine and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
  • Koltsova E; Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Medicine and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
  • Lee H; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Walsh M; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Duttweiler R; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Whetstine JR; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Yen TJ; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Issa JP; Coriell Institute for Medical Research, Camden, New Jersey.
  • Bellacosa A; Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Nuclear Dynamics and Cancer Program, Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania. Electronic address: Alfonso.Bellacosa@fccc.edu.
Gastroenterology ; 164(6): 921-936.e1, 2023 05.
Article en En | MEDLINE | ID: mdl-36764492
BACKGROUND & AIMS: Aberrant DNA methylation is frequent in colorectal cancer (CRC), but underlying mechanisms and pathologic consequences are poorly understood. METHODS: We disrupted active DNA demethylation genes Tet1 and/or Tdg from ApcMin mice and characterized the methylome and transcriptome of colonic adenomas. Data were compared to human colonic adenocarcinomas (COAD) in The Cancer Genome Atlas. RESULTS: There were increased numbers of small intestinal adenomas in ApcMin mice expressing the TdgN151A allele, whereas Tet1-deficient and Tet1/TdgN151A-double heterozygous ApcMin colonic adenomas were larger with features of erosion and invasion. We detected reduction in global DNA hypomethylation in colonic adenomas from Tet1- and Tdg-mutant ApcMin mice and hypermethylation of CpG islands in Tet1-mutant ApcMin adenomas. Up-regulation of inflammatory, immune, and interferon response genes was present in Tet1- and Tdg-mutant colonic adenomas compared to control ApcMin adenomas. This up-regulation was also seen in murine colonic organoids and human CRC lines infected with lentiviruses expressing TET1 or TDG short hairpin RNA. A 127-gene inflammatory signature separated colonic adenocarcinomas into 4 groups, closely aligned with their microsatellite or chromosomal instability and characterized by different levels of DNA methylation and DNMT1 expression that anticorrelated with TET1 expression. Tumors with the CpG island methylator phenotype (CIMP) had concerted high DNMT1/low TET1 expression. TET1 or TDG knockdown in CRC lines enhanced killing by natural killer cells. CONCLUSIONS: Our findings reveal a novel epigenetic regulation, linked to the type of genomic instability, by which TET1/TDG-mediated DNA demethylation decreases methylation levels and inflammatory/interferon/immune responses. CIMP in CRC is triggered by an imbalance of methylating activities over demethylating activities. These mice represent a model of CIMP CRC.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Adenocarcinoma / Adenoma / Neoplasias del Colon Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Gastroenterology Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Adenocarcinoma / Adenoma / Neoplasias del Colon Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Gastroenterology Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos